These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 32051451)

  • 1. Denosumab for dialysis patients with osteoporosis: A cohort study.
    Kunizawa K; Hiramatsu R; Hoshino J; Mizuno H; Ozawa Y; Sekine A; Kawada M; Sumida K; Hasegawa E; Yamanouchi M; Hayami N; Suwabe T; Sawa N; Ubara Y; Takaichi K
    Sci Rep; 2020 Feb; 10(1):2496. PubMed ID: 32051451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypocalcemia and bone mineral density changes following denosumab treatment in end-stage renal disease patients: a meta-analysis of observational studies.
    Thongprayoon C; Acharya P; Acharya C; Chenbhanich J; Bathini T; Boonpheng B; Sharma K; Wijarnpreecha K; Ungprasert P; Gonzalez Suarez ML; Cheungpasitporn W
    Osteoporos Int; 2018 Aug; 29(8):1737-1745. PubMed ID: 29713798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of denosumab on bone metabolism and bone mineral density in kidney transplant patients: a systematic review and meta-analysis.
    Thongprayoon C; Acharya P; Aeddula NR; Torres-Ortiz A; Bathini T; Sharma K; Ungprasert P; Watthanasuntorn K; Suarez MLG; Salim SA; Kaewput W; Chenbhanich J; Mao MA; Cheungpasitporn W
    Arch Osteoporos; 2019 Mar; 14(1):35. PubMed ID: 30852679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of denosumab in osteoporotic hemodialysed patients.
    Festuccia F; Jafari MT; Moioli A; Fofi C; Barberi S; Amendola S; Sciacchitano S; Punzo G; Menè P
    J Nephrol; 2017 Apr; 30(2):271-279. PubMed ID: 27394428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impaired residual renal function predicts denosumab-induced serum calcium decrement as well as increment of bone mineral density in non-severe renal insufficiency.
    Miyaoka D; Imanishi Y; Ohara M; Hayashi N; Nagata Y; Yamada S; Mori K; Emoto M; Inaba M
    Osteoporos Int; 2019 Jan; 30(1):241-249. PubMed ID: 30187112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Denosumab associated with bone density increase and clinical improvement in a long-term hemodialysis patient. Case report and review of the literature.
    Dusilova Sulkova S; Horacek J; Safranek R; Gorun P; Viklicky O; Palicka V
    Acta Medica (Hradec Kralove); 2014; 57(1):30-3. PubMed ID: 25006661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypocalcemia and bone mineral changes in hemodialysis patients with low bone mass treated with denosumab: a 2-year observational study.
    Hiramatsu R; Ubara Y; Sawa N; Sakai A
    Nephrol Dial Transplant; 2021 Sep; 36(10):1900-1907. PubMed ID: 33544866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term safety and effectiveness of denosumab in Japanese patients with osteoporosis: 3-year post-marketing surveillance study.
    Tanaka S; Mizutani H; Tsuruya E; Fukuda R; Kuge K; Okubo N
    J Bone Miner Metab; 2021 May; 39(3):463-473. PubMed ID: 33387064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Denosumab increases sublesional bone mass in osteoporotic individuals with recent spinal cord injury.
    Gifre L; Vidal J; Carrasco JL; Muxi A; Portell E; Monegal A; Guañabens N; Peris P
    Osteoporos Int; 2016 Jan; 27(1):405-10. PubMed ID: 26423406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three-year results of denosumab treatment for osteoporosis in women with rheumatoid arthritis and primary osteoporosis: A clinical observational study.
    Mochizuki T; Yano K; Ikari K; Hiroshima R; Nasu Y; Okazaki K
    Mod Rheumatol; 2021 May; 31(3):600-606. PubMed ID: 32815449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Teriparatide and Denosumab in Patients Switching From Long-Term Bisphosphonate Use.
    Lyu H; Zhao SS; Yoshida K; Tedeschi SK; Xu C; Nigwekar SU; Leder BZ; Solomon DH
    J Clin Endocrinol Metab; 2019 Nov; 104(11):5611-5620. PubMed ID: 31265071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.
    Bone HG; Wagman RB; Brandi ML; Brown JP; Chapurlat R; Cummings SR; Czerwiński E; Fahrleitner-Pammer A; Kendler DL; Lippuner K; Reginster JY; Roux C; Malouf J; Bradley MN; Daizadeh NS; Wang A; Dakin P; Pannacciulli N; Dempster DW; Papapoulos S
    Lancet Diabetes Endocrinol; 2017 Jul; 5(7):513-523. PubMed ID: 28546097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once-weekly teriparatide in hemodialysis patients with hypoparathyroidism and low bone mass: a prospective study.
    Sumida K; Ubara Y; Hoshino J; Mise K; Hayami N; Suwabe T; Kawada M; Imafuku A; Hiramatsu R; Hasegawa E; Yamanouchi M; Sawa N; Takaichi K
    Osteoporos Int; 2016 Apr; 27(4):1441-1450. PubMed ID: 26525045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of bone remodeling agents following teriparatide treatment.
    Burkard D; Beckett T; Kourtjian E; Messingschlager C; Sipahi R; Padley M; Stubbart J
    Osteoporos Int; 2018 Jun; 29(6):1351-1357. PubMed ID: 29541794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Denosumab-Associated Severe Hypocalcemia in Dialysis-Dependent Patients.
    Schoenmakers I; Fraser WD
    JAMA; 2024 Jun; 331(21):1864-1865. PubMed ID: 38717748
    [No Abstract]   [Full Text] [Related]  

  • 16. Using early biomarker data to predict long-term bone mineral density: application of semi-mechanistic bone cycle model on denosumab data.
    Zheng J; van Schaick E; Wu LS; Jacqmin P; Perez Ruixo JJ
    J Pharmacokinet Pharmacodyn; 2015 Aug; 42(4):333-47. PubMed ID: 26123919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes of Bone-Related Minerals during Denosumab Administration in Post-Menopausal Osteoporotic Patients.
    Suzuki T; Nakamura Y; Kato H
    Nutrients; 2017 Aug; 9(8):. PubMed ID: 28805705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of denosumab on bone mineral density and bone metabolism in patients with end-stage renal disease: A systematic review and meta-analysis.
    Gu Z; Yang X; Wang Y; Gao J
    Hemodial Int; 2023 Oct; 27(4):352-363. PubMed ID: 37264758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the effects of denosumab with either active vitamin D or native vitamin D on bone mineral density and bone turnover markers in postmenopausal osteoporosis.
    Suzuki T; Nakamura Y; Tanaka M; Kamimura M; Ikegami S; Uchiyama S; Kato H
    Mod Rheumatol; 2018 Mar; 28(2):376-379. PubMed ID: 28397581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lower response to denosumab in diabetes patients on hemodialysis.
    Han SH; Jo HA; Han KH; Han SY
    Clin Nephrol; 2022 Feb; 97(2):70-77. PubMed ID: 34448695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.